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David Criddle, PhD,† and Robert Sutton, DPhil, FRCS*Objectives: Mitochondrial permeability transition pore inhibition is a
promising approach to treat acute pancreatitis (AP). We sought to deter-
mine (i) the effects of the mitochondrial permeability transition pore inhib-
itor 3,5-seco-4-nor-cholestan-5-one oxime-3-ol (TRO40303) on murine
and human pancreatic acinar cell (PAC) injury induced by fatty acid ethyl
esters (FAEEs) or taurolithocholic acid-3-sulfate and (ii) TRO40303 phar-
macokinetics and efficacy in experimental alcoholic AP (FAEE-AP).
Methods: Changes in mitochondrial membrane potential (Δψm), cyto-
solic Ca2+ ([Ca2+]c), and cell fate were examined in freshly isolated murine
or human PACs by confocal microscopy. TRO40303 pharmacokinetics were
assessed in cerulein-induced AP and therapeutic efficacy in FAEE-AP in-
duced with palmitoleic acid and ethanol. Severity of AP was assessed by
standard biomarkers and blinded histopathology.
Results: TRO40303 prevented loss of Δψm and necrosis induced by
100 μM palmitoleic acid ethyl ester or 500 μM taurolithocholic acid-
3-sulfate in murine and human PACs. Pharmacokinetic analysis found
TRO40303 accumulated in the pancreas. A single dose of 3 mg/kg
TRO40303 significantly reduced serum amylase (P = 0.043), pancreatic
trypsin (P = 0.018), and histopathology scores (P = 0.0058) in FAEE-AP.
Conclusions: TRO40303 protects mitochondria and prevents necrotic
cell death pathway activation in murine and human PACs, ameliorates the
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A cute pancreatitis (AP) occurs in up to 100 per 100,000 per-sons per year, mostly caused by cholelithiasis or excessive al-
cohol intake.1 Twenty percent of cases are severe, these being
frequently complicated by pancreatic necrosis, multiple organ
failure, prolonged hospitalization, and death.2 Despite several
hundred randomized clinical trials to date, there is no internation-
ally validated specific drug therapy for this common disease, one
of the commonest gastrointestinal emergencies requiring hospital-
ization in the United States costing approximately $2.6 billion
per annum.3
Pancreatic necrosis is characterized by severe patho-
physiological changes that include mitochondrial swelling,
plasmalemmal disruption, and leakage of activated digestive en-
zymes and other cellular contents, which trigger acute exudative
inflammation of the surrounding tissue.1,4 Necrosis is a key pre-
dictor of disease outcome in patients with AP.2 Because clinical
pancreatic necrosis develops typically over several days rather
than hours, there is a therapeutic window that could be exploited
to prevent necrosis if an appropriate mechanism can be targeted.
Mitochondria have been increasingly implicated in pancreatic ac-
inar cell (PAC) injury, necrosis, and AP.5–7 Pancreatitis toxins
cause acinar cytosolic calcium overload through excessive release
from the endoplasmic reticulum calcium store sustained by con-
tinued calcium entry.8 Cytosolic calcium overload causes mito-
chondrial matrix calcium overload, inducing the mitochondrial
permeability transition pore (MPTP), a nonspecific inner mito-
chondrial membrane channel that results in loss of mitochondrial
membrane potential (Δψm) essential for ATP production.
9 Inhibi-
tion of the MPTP has been shown to sustain ATP production in
PACs under stress and is potentially a suitable strategy for the
treatment of AP.10
An important group of pancreatitis toxins are fatty acid ethyl
esters (FAEEs), nonoxidative metabolites of ethanol formed in the
pancreas more than any other organ per unit weight of tissue,
reaching high concentrations following excess ethanol consump-
tion.11 We have shown FAEEs to cause pancreatic acinar cytosolic
calcium overload through induction of second messenger receptor
calcium-channel release from the endoplasmic reticulum,12 leading
to mitochondrial impairment and diminished ATP production,13
alongside premature intracellular digestive enzyme activation.14
We have since developed an in vivo AP model derived from these
findings, induced by simultaneous administration of ethanol and
fatty acid (FAEE-AP).15 Inhibition of FAEE synthesis or FAEE
hydrolysis reduced the severity of AP, confirming FAEEs as thePancreas • Volume 47, Number 1, January 2018
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sporin A analog Debio-025 have indicated that inhibition of the
MPTP is protective in FAEE-AP, consistent with findings in
other models.10
TRO40303 (3,5-seco-4-nor-cholestan-5-one oxime-3-ol)
is a cholesterol-oxime cytoprotective compound developed by
Trophos (since acquired by Roche) that binds to the outer mito-
chondrial translocator protein (TSPO), delaying MPTP opening
and cell death in rat cardiomyocytes, and has been shown to sig-
nificantly reduce the extent of myocardial infraction in a rat
model.16 TRO40303 protected HepG2 cells and primary mouse
embryonic hepatocytes from palmitate intoxication and signifi-
cantly reduced mortality in murine FAS-induced hepatotoxicity.17
Results from a randomized safety and tolerance phase 1 trial
showed that TRO40303 can be safely administered intravenously
in humans at doses expected to be pharmacologically active.18 We
have previously demonstrated that 10 μM TRO40303 protects
PACs from bile acid–induced mitochondrial injury and necrosis
in vitro, whereas 3 mg/kg TRO40303 reduced the severity of
cerulein (CER-AP)–induced and bile acid (taurolithocholic acid-
3-sulfate [TLCS]–AP)–induced experimental AP in vivo.10 Here
we have evaluated the effects of a range of concentrations of
TRO40303 on murine and human PACs exposed to FAEEs or
TLCS. Because cyclophilin D (Cyp-D) is an integral modulator
ofMPTPopening, we also evaluated whether Cyp-D is a potential
target of TRO40303. To determine in vivo effects, we assessed
pharmacokinetics of TRO40303 over 24 hours following admin-
istration of a range of doses in both naive mice and in murine ex-
perimental AP, to select a dose that we then tested in FAEE-AP.MATERIALS AND METHODS
Human Pancreatic Sampling
Normal human pancreatic tissue samples were obtained from
consenting patients with no history of jaundice or chronic pancre-
atitis who were undergoing elective left pancreatectomy, resec-
tions for duodenal tumors or nonobstructed right-sided cancer
resections at the Royal Liverpool University Hospital (Liverpool
Adult Local Research Ethics Committee approval 03/12/242/A).
Isolation of human PACs was performed as previously de-
scribed.19 The time from sampling to the start of cell isolation pro-
cedure was 10 minutes or less.
Animals
Wild-type 8- to 12-week-old CD1 mice, weighing approxi-
mately 30 g each, were used for PAC isolation and cell experiments.
C57Bl/6 mice heavier than 25 g were used for in vivo experiments.
Confocal Microscopy
Acinar cells were loaded with appropriate dye(s) and im-
aged using Zeiss LSM 510 and 710 confocal microscopes (Jena,
Germany), equipped with multiple laser lines. Cells were visualized
with a C-Apochromat 63X water immersion objective. Between
150 and 180 μL of PACs suspended in Na HEPES were placed
in a microplate, and healthy-looking duplets or triplets of acinar
cells with intact loading of fluorescent dyes were selected for record-
ing of Δψm and [Ca2+]c.10,12,13,15 To assess mitochondrial function,
live acinar cells were loaded with 50 nM tetramethylrhodamine
methyl ester (TMRM; excitation 543 nm, emission >550 nm), a
dye used to measure Δψm. Similarly to measure changes in [Ca2+]c,
cells were loaded with Fluo-4 (excitation 488 nm, emission
505 nm) by incubation in solution containing 3 μM Fluo-4 AM.
Typically cells were pretreated for 30 minutes with TRO40303© 2017 Wolters Kluwer Health, Inc. All rights reserved.or vehicle prior to the start of each experiment. After the assess-
ment of baseline fluorescence levels (F0), cells were stimulated
with 100 μM palmitoleic acid ethyl ester (POAEE) or 500 μM
TLCS and at the end of each experiment perfused with 10 μM car-
bonyl cyanide m-chlorophenylhydrazone as a positive control.
Cells were imaged every 5 to 10 seconds for measurement of
Δψm and [Ca
2+]c, in the absence or presence of TRO40303 at a
concentration of 1 μM (T1), 3 μM (T3), or 10 μM (T10). In some
experiments, cells were coloaded with TMRM and Fluo 4 to mea-
sure (Δψm) and [Ca
2+]c respectively, using the multitrack configu-
ration of the LSM510 system. Both TMRMand Fluo-4 fluorescent
signals were normalized to baseline fluorescence (F/F0).
For assessment of necrotic cell death pathway activation,
1 μM propidium iodide (PI; excitation 543 nm, emission
630–693 nm) was used to evaluate plasma membrane rup-
ture.10,12,13 Isolated PACs from each animal or human sample
were divided into 3 groups and imaged: (i) PAC only (negative
control): acinar cells incubated with Na HEPES for 30 minutes;
(ii) PAC + toxin (500 μM TLCS or 100 μM POAEE); acinar cells
incubated with toxin for 30 minutes; (iii) PAC + toxin + T1/T3/
T10: acinar cells incubated with 1, 3, or 10 μM TRO40303 and
toxin simultaneously. Sixteen randomly selected fields of view
were taken of each mouse isolate, and the total number of cells
displaying PI uptakewas counted per field. This gave a percentage
ratio for each field, averaged across fields, converted to a mean ±
SEM for a minimum of 3 mice and 2 or 3 human samples per ex-
perimental group. Each experiment was performed in a blinded
fashion, with the observer choosing the fields and the observer un-
dertaking image analysis blind to the treatment groups. Necrotic
cell death pathway activation induced by 50 μM POAEE was also
evaluated using time-lapse recording of PI (2 μg/mL; excitation
543 nm, emission >640 nm) signals at 37°C for 13 hours using
a plate reader. In each experiment, 6 wells (on a 96-well plate)
were allocated to each treatment group from which an average
was calculated. T1, T3, and T10 were added 30 minutes prior to
the addition of 50 μM POAEE.
Surface Plasmon Resonance
The Surface Plasmon Resonance technology–based
Biacore X100 (GE Healthcare, Amersham, United Kingdom)
was used to evaluate the interaction of TRO40303 with
Cyp-D.20 All experiments were carried out using buffer contain-
ing Tris-HCl pH 7.6, NaCl 150 mM, 0.05% surfactant p20, and
5% of dimethyl sulfoxide as a running buffer, at a constant flow
rate of 30 μL/min at room temperature. The protein, Cyp-D, was
immobilized directly and covalently on a CM5 chip (BIAcore,
Amersham, United Kingdom) by using standard primary amine cou-
pling. All data analyses were carried out using BIA evaluation soft-
ware version 3.0 (GE Healthcare, Amersham, United Kingdom).
Tissue and Plasma TRO40303 Exposure
Pharmacokinetics were assessed following intraperitoneal
(IP) administration of 3 or 10 mg/kg TRO40303 in a liposomal
preparation to C57Bl/6 mice. A maximum of 0.25 mL of blood
was collected into lithium heparin tubes at 15 and 30 minutes
and 1, 2, 4, 8, and 24 hours after drug administration (3 mice
per time point). Blood samples were cooled on ice, and plasma
samples prepared within 60minutes of sampling by centrifugation
at 1500g at 4°C for 10 minutes then stored at −20°C until analysis.
For measurement of pancreatic levels, TRO40303 was adminis-
tered by IP injection to mice at 3 mg/kg in liposomes, then
pancreata were isolated at 15 minutes, 2 hours, and 24 hours after
injection (3 mice per time point) and washed with saline. Samples
were frozen and stored at −20°C until analysis.www.pancreasjournal.com 19
FIGURE 1. TRO40303 reduces loss of Δψm induced by FAEE.
Palmitoleic acid ethyl ester (100 μM) induced a sharp fall in Δψm;
this fall was reduced by pretreatment with 10 μMTRO40303 (T10),
although there was no protection from pretreatment with 1 μM
TRO40303 (T1).
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levels in the pancreas to be similar to those achieved in the heart
using 1mg/kg TRO40303 administered by an intravenous route,16
confirmation that adequate levels of TRO40303 could be
achieved in experimental AP was required. TRO40303 levels
were therefore measured in blood (plasma) and pancreata sampled
15 minutes after administration of the liposomal preparation of 1,
3, or 10 mg/kg of TRO40303 in cerulein-induced AP, the most
widely used model of AP.1 Plasma obtained from blood by imme-
diate centrifugation (2500 revolutions/min at 4°C for 15 minutes)
and pancreatic samples were stored at −20°C for bioanalysis.
Thawed samples were extracted with acetonitrile, centrifuged, pu-
rified on SPEC C2 cartridge (Varian, Palo Alto, Calif ), and ana-
lyzed by high-performance liquid chromatography–tandem mass
spectrometry together with calibration standards. Analysis was
carried out on an Alliance 2695 (Waters, Guyancourt, France) sys-
tem interfaced with an API Quattro Micro (Waters) mass spec-
trometry detector. Calculations were undertaken using Waters
Quan Lynx software version 1.40.
Experimental Acute Pancreatitis
Alcoholic AP was induced by IP injection of ethanol and
palmitoleic acid (FAEE-AP), a fatty acid that combines with eth-
anol in the pancreas to form FAEEs, the principal agents of PAC
injury from ethanol excess.15 Mice received 2 IP injections of
1.32 g/kg ethanol and 1.5 mg/kg palmitoleic acid (dissolved in
the ethanol), each 1 hour apart, to induce AP. For treatment,
3 mg/kg TRO40303 (selected on the basis of the pharmacokinetic
analyses and prior experience with TLCS-AP and CER-AP) was
administered intraperitoneally 1 hour after the last injection.
The experimental groups were (i) controls with no toxin or
treatment; (ii) positive controls, that is, FAEE-AP alone; and (iii)
treatment group, that is, FAEE-AP with 3 mg/kg TRO40303 (6
per group). The dose was optimized based on its efficacy in
CER-AP and TLCS-AP.10 TRO40303 stock solution in liposomes
(20 mg/mL) was diluted into saline and injected intraperitoneally
using a constant volume of 2.5 mL/kg. Animals were killed hu-
manely 24 hours after induction of FAEE-AP for assessment of
biochemical and histological parameters of severity.
All in vivo experiments complied with the Animals (Scien-
tific Procedures) Act 1986 (Project Licence PPL70/8109) as ad-
ministered by the Home Office UK.
Biochemical Parameters of FAEE-AP Severity
The biochemical parameters of severity were serum amylase,
pancreatic trypsin, pancreatic myeloperoxidase (MPO) activity,
and lung MPO activity. Amylase levels were tested using a ki-
netic method with a Roche automated clinical chemistry analyzer
(Burgess Hill, United Kingdom). Trypsin activity was measured
by a fluorogenic assay, using Boc-Gln-Ala-Arg-AMC substrate
converted by trypsin to a fluorescent product (excitation 380 nm,
emission 440 nm).21 For MPO activity, 20 μL of extract was added
to 200 μL phosphate buffer (100 mM, pH 5.4, with 0.5%HETAB)
and 20 μL 3,3′,5,5′-tetramethylbenzidine (20 mM) in dimethyl
sulfoxide. This mixture was incubated at 37°C for 3 minutes,
followed by addition of 50 μL of H2O2 (0.01%) for further incu-
bation over 3 minutes. The difference of absorbance between 0
and 3 minutes at 650 nm was calculated using a standard curve
compiled using human MPO.22
Histopathologic Parameters of AP Severity
Pancreatic tissue was fixed in formaldehyde, and standard
hematoxylin-eosin sections were prepared. Scoring of edema
(0–3), leukocyte infiltration (0–3), and necrosis (0–3) was20 www.pancreasjournal.comundertaken by 2 independent, blinded investigators in 10 high-
power fields per slide per mouse10,15; 200 magnification was
used throughout. Scores were summated, then means ± SEM his-
tology scores were calculated for each experimental group.
Statistical Analysis
Data are presented as means ± SEM. Comparisons were per-
formed using the unpaired Student’s t-test orχ2 test as appropriate,
withP < 0.05 taken as theminimum level of statistical significance.RESULTS
TRO40303 Reduces Loss of Δψm and Necrotic Cell
Death Pathway Activation From POAEE and TLCS
in a Concentration-Dependent Manner
POAEE (100 μmol/L with 850 mmol/L ethanol to maintain
solubility) induced a sharp fall in Δψm in murine PACs and rise
in PI uptake; pretreatment with 10 μMTRO40303 significantly re-
duced the extent of depolarization (Fig. 1) and PI uptake (Fig. 2A).
Comparison of the effects of 1, 3, and 10 μMTRO40303 on PI up-
take induced by 50 μmol/L POAEE over 13 hours demonstrated
that the protection afforded by TRO40303 is concentration depen-
dent, with increasing effect at increasing concentrations (Fig. 2B).
Because we previously found 10 μM TRO40303 inhibited
falls inΔψm and prevented TLCS-induced necrotic cell death path-
way activation in isolated murine and human PACs,10 but had not
determined the concentration-dependence of these effects, we
tested lower doses of TRO40303 on TLCS-induced loss of Δψm,
[Ca2+]c, and PI update in murine and human PACs (Supplemental
Figures 1 and 2, http://links.lww.com/MPA/A618). Pretreatment
with TRO40303 inhibited depolarization, although 3 μM showed
a trend to be more effective than 1 μMTRO40303. Consistent with
this mitochondrial protection, we found TRO40303 reduced PI up-
take in both murine and human PACs (Supplemental Figure 2,
http://links.lww.com/MPA/A618) more effectively using 3 μM
than 1 μMTRO40303. Protection from necrotic cell death pathway
activation achieved statistical significance only at the higher con-
centration in both murine and human PACs but not to the same ex-
tent as observed with 10 μM TRO40303.10 In keeping with these
effects, clearance of [Ca2+]c was more effective with higher© 2017 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Effect of TRO40303 on necrotic cell death pathway
activation induced by FAEE in PACs. A, Palmitoleic acid ethyl ester
(100 μM) exposure increased PI uptake, whereas pretreatment
with TRO40303 (10 μM) reduced necrotic cell death pathway
activation in response to POAEE (POAEE vs POAEE plus TRO40303,
*P < 0.05). B, Simultaneous comparison of PI uptake in response
to POAEE (50 μM) alone or with 1, 3, or 10 μM TRO40303
pretreatment. Aggregate curves and paired analysis showed that
all concentrations protected PACs against POAEE-induced cell
death, in a concentration-dependentmanner; n indicates number
of independent experiments.
FIGURE 3. TRO40303 levels in plasma and pancreas following
administration of a range of doses (1–10 mg/kg). A, Plasma level
of TRO40303 expressed in μg/mL during 24 hours after IP
administration of 3 or 10 mg/kg TRO40303 in liposomes
contrasted with plasma level of TRO40303 15 minutes after IP
administration in CER-AP. B, Pancreatic concentration of
TRO40303 expressed in μg/g tissue during 24 hours after IP
administration of 3 mg/kg TRO40303 in liposomes contrasted
with plasma level of TRO40303 15 minutes after administration
in CER-AP.
Pancreas • Volume 47, Number 1, January 2018 TRO40303 Reduces Pancreatic Injury and FAEE-APconcentrations of TRO40303 (Supplemental Figure 1, http://links.
lww.com/MPA/A618).
TRO40303 Does Not Bind to Cyclophilin D
Using surface plasmon resonance, we evaluated the bind-
ing affinity of TRO40303 with Cyp-D, a regulator of the MPTP.9
TRO40303 did not bind to Cyp-D (Supplemental Figure 3,
http://links.lww.com/MPA/A618). Moreover, no interaction be-
tween TRO40303 and Cyp-D was detected by nuclear magnetic
resonance spectroscopy (data not shown). These findings in-
dicate that TRO40303 inhibits the MPTP via a Cyp-D–
independent mechanism.
TRO40303 Levels in Plasma and Pancreas
TRO40303 is distributed throughout the body with signifi-
cant affinity for steroidogenic tissues and substantial levels in
organs with high numbers of mitochondria.16 The liposomal
preparation of TRO40303 was prepared for IP injection, an eas-
ier parenteral route than the previously studied intravenous
route16 for administration in murine AP models. We considered© 2017 Wolters Kluwer Health, Inc. All rights reserved.determination of pancreatic levels to be critical as protection of
the pancreas from opening of the MPTP is the primary purpose
of this strategy.10 In naive mice receiving 3 mg/kg TRO40303 in
the liposomal preparation, plasma levels reached approximately
5 μg/mL 2 hours after injection (Fig. 3A), with concentrations in
the pancreas approximately 2.5 μg/g at the same time (Fig. 3B).
This corresponded with the concentration achieved in the heart
5 minutes after intravenous injection of 1 mg/kg TRO40303 for-
mulated intoβ-cyclodextrin in a rat model of coronary occlusion.16
Although 10 mg/kg TRO40303 in the liposomal preparation gave
significantly higher plasma levels, levels were undetectable in
plasma 24 hours following either dose. Nevertheless, at 24 hours
after 3 mg/kg TRO40303 in the liposomal preparation, pancreatic
levels were approximately 1 μg/g, indicative of a prolonged half-
life (>12 hours) in the pancreas following a single dose and of po-
tential efficacy in that organ (at approximately 2–5 μM) over
24 hours at that dose. Furthermore, plasma and pancreatic levels
of TRO40303 at 15 minutes after injection were significantly higher
in CER-AP (Figs. 3A, B; 1–10 mg/kg TRO40303). Therefore,
3 mg/kg TRO40303 was used to test the efficacy of this
compound in FAEE-AP.www.pancreasjournal.com 21
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Pancreatic Histopathology in FAEE-AP
Fatty acid ethyl ester–induced AP parallels acute alcoholic
pancreatitis through in vivo formation of toxic ethanol metabo-
lites that we have previously demonstrated to induce overload of
[Ca2+]c and mitochondrial impairment in isolated PACs.
12,13 Fatty
acid ethyl ester–induced AP was found to cause significant eleva-
tions in serum amylase, pancreatic trypsin, and MPO, as well as
lungMPO, indicating neutrophil infiltration (Fig. 4). Correspond-
ing significant elevations in pancreatic edema, inflammatory cell
infiltration, and parenchymal necrosis were confirmed through
assessment of histological sections, reflected in significant eleva-
tion of the overall histology score (Fig. 5). As TRO40303 protects
mitochondria and isolated PACs from POAEE-induced injury, we
assessed the impact of the liposomal preparation of TRO40303
(3 mg/kg) on FAEE-AP. TRO40303 administered as a treatment
1 hour after induction of FAEE-AP significantly reduced FAEE-
AP–induced increases in serum amylase, pancreatic trypsin,
andMPO, as well as lungMPO (Fig. 4). There were concomitant
significant reductions in edema, inflammation, necrosis, and
overall histopathology scores as a result of TRO40303 in
FAEE-AP (Fig. 5).
DISCUSSION
This study has demonstrated the protective effects of
TRO40303 on PAC injury developing in response to FAEEs in
vitro and the efficacy of TRO40303 in a clinically relevant exper-
imental model of alcoholic AP in vivo. The FAEE-AP model is
clinically relevant as high levels of FAEEs accumulate in the pan-
creas following acute alcohol intoxication, in contrast to other or-
gans commonly damaged by alcohol,11 and substantial evidence
now implicates FAEEs in PAC,12,13,15 as well as pancreatic ductal
cell injury.23,24 Epidemiological studies have also shown amarkedFIGURE 4. TRO40303markedly reduced biochemical responses of FAEE-
(A) serum amylase, (B) pancreatic trypsin activity, (C) pancreatic, and (D)
TRO40303 (3 mg/kg IP) reduced all biochemical parameters of severity
*P < 0.05 FAEE-AP vs FAEE-AP plus TRO40303).
22 www.pancreasjournal.comincrease in the level of alcohol consumption in recent decades,
which parallels a sustained rise in the incidence of AP.25 Fatty acid
ethyl esters as well as TLCS induce toxic sustained calcium over-
load in PACs, leading to mitochondrial dysfunction and necro-
sis,12,13 and the combination of ethanol with palmitoleic acid
induces significant pancreatic damage with extensive acinar cell
edema, neutrophil infiltration, and necrosis in vivo.15 Although
not targeting calcium overload per se, TRO40303 inhibits critical
downstream effects on the mitochondria controlling cell fate.16–18
The protective effects of TRO40303 on POAEE-induced PACmi-
tochondrial dysfunction and necrosis, as well as the attenuation of
FAEE-AP severity when given after disease induction, demon-
strate the potential applicability of TRO40303 as a treatment for
human alcohol-induced AP. This study now adds a third in vivo
AP model in which TRO40303 has been shown to be effective
when administered after disease induction. The novel human data
support translational potential for TRO4303; we have previously
shown TRO40303 protects murine PACs from TLCS-induced in-
jury by similar mechanisms, here confirmed in human PACs. The
cumulative data on the effects of TRO40303 contrast with previ-
ous preclinical trials of drugs for AP, the majority of which have
been conducted in a single model only (most often CER-AP)1
with treatment given prophylactically before disease induction.
In the majority of patients developing AP, however, prophylactic
administration of a drug is not possible.
The mitochondrion is the powerhouse of the cell. There is ev-
idence indicating that sepsis-induced multiple organ failure de-
pends on the development of mitochondrial dysfunction and
consequent cellular energetic failure.26 Multiorgan failure is also
the leading cause of death in patients with SAP.2 TRO40303 is
an MPTP modulator that has been shown to be protective in mul-
tiple cellular and animal models characterized by stress-induced
mitochondrial permeabilization,16–18,27,28 although whether TSPO
binding is the primary mechanism of action remains to beAP. Fatty acid ethyl ester–induced AP caused significant elevations in
lungMPO activity. Administration of the liposomal preparation of
(mean ± SEM >6 animals/group; #P < 0.05, control vs FAEE-AP;
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 5. TRO40303markedly reduced pancreatic histopathology in FAEE-AP. Fatty acid ethyl ester–induced AP led to significant elevations
in (A) overall histology score, (B) necrosis, (C) edema, and (D) inflammatory cell infiltrate. Administration of the liposomal preparation of
TRO40303 (3 mg/kg IP) markedly reduced all histopathologic markers of severity (mean ± SEM >6 animals/group; #P < 0.05, control vs
FAEE-AP; *P < 0.05 FAEE-AP vs FAEE-AP plus TRO40303). E, Representative images showing normal pancreatic histology, typical
histopathology from FAEE-AP, and typical histopathology after treatment with TRO40303.
Pancreas • Volume 47, Number 1, January 2018 TRO40303 Reduces Pancreatic Injury and FAEE-APconfirmed.29 Pharmacokinetic profiles of TRO40303 have shown
accumulation at substantial levels within the lungs, liver, heart,
and kidneys,16 all organs contributing to organ failure in AP.
Levels were higher in experimental AP than in naive animals, pos-
sibly due to reduction in the speed of metabolism and/or excretion
of the drug, a consideration in the design of any future human tri-
als. Nevertheless, the accumulation in vital organs suggests that
TRO40303 might also usefully prevent or lessen systemic organ
dysfunction in AP through direct effects on these organs, suggest-
ing promise in this approach.
This study strengthens an established rationale for targeting
the MPTP to treat a range of acute and chronic conditions in
which necrotic cell death is a critical and/or prominent feature.9,29
Cyclosporin A is the only licensed drug used experimentally to in-
hibit formation of the MPTP, the mechanism of action being inhi-
bition of Cyp-D, the most widely recognized regulator of the
MPTP. Clinical trials testing the efficacy of cyclosporin A in this
regard have been undertaken, with mixed results: a pilot study
found reduction in the size and severity of myocardial infarction
associated with cyclosporinA treatment prior to percutaneous cor-
onary intervention,30 not replicated in a larger study.31 The immu-
nosuppressive actions of cyclosporin A essential to its primary© 2017 Wolters Kluwer Health, Inc. All rights reserved.therapeutic use in controlling autoimmunity and allograft rejec-
tion, however, preclude widespread use in conditions where the
MPTP is a target. For example, AP predisposes to local and sys-
temic infection, which contributes significantly to mortality1,2;
the powerful immunosuppressive actions of cyclosporin A are
likely to impact negatively on infective outcomes in AP. There
are continuing major efforts to develop new, specific inhibitors
of Cyp-D, although none is ready for first-in-man study.32
TRO40303, which does not have the immunosuppressive actions
of cyclosporinA but which has been shown experimentally to have
significant impact on a number of forms of organ injury, has also
been tested in a phase 2 trial of cardiac preservation following
acute myocardial infarction, but was not found to have significant
protective effects.33 While the mechanism of action of TRO40303
remains to be confirmed,29 our study shows that TRO40303 did
not bind to Cyp-D. Nevertheless, because TRO40303 may have
both pancreatic as well as systemic protective effects in AP, and
the therapeutic window is potentially longer than in that inmyocar-
dial infarction, there is perhaps a higher chance of efficacy in AP
than inmyocardial infarction.While phenotypic screens have iden-
tified newMPTP inhibitors, and a number of powerful compounds
have been identified, all present challenges: cinnamic anilides werewww.pancreasjournal.com 23
Javed et al Pancreas • Volume 47, Number 1, January 2018found to be no more effective than cyclosporin A in experi-
mental myocardial infarction, isoxazoles are unstable in vivo,
and benzamides impair ATP generation.29 The small number of
agents in development for the treatment of AP and the extensive
work already undertaken to develop TRO40303 as a drug support
the case to test TRO40303 in human AP.
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